After a long altercation apropos the quality of stents in which are manufactured in India, besides another brand which has been compared to an Indian stent with a foreign brand has been deciphered to be equally good.
The study’s findings were presented at the prestigious international conference on Non-Surgical Cardiac interventions – TCT (Trans Catheter Interventions) – on September 22 in San Diego, US.
In the recently conducted randomized trial to compare an India made stent Supra flex with the world leader Xience stent from Abbott Vascular, the Supra flex sirolimus-eluting coronary stent manufactured by SMT in Surat emerged to be as good as the Xience stent made in Europe and the US.
The TALENT trial was conceived by Prof. Upendra Kaul, a well known interventional cardiologist who is currently the chairman of Batra Heart Center, New Delhi, and Prof. Patrick Surreys, an internationally acclaimed researcher in this field from the Netherlands.
Kaul explained, “The aim of the study was to test the hypothesis that both stents are equal in performance and safety. To dispel the belief that imported coronary devices are better, it needed a scientific study without any bias.”
In February, last year, when the Indian government decided to cap the prices of coronary stents, there was a dramatic reduction in prices from an average of USD 1,800 for the drug-eluting stent (DES) to USD 480 irrespective of the country they were manufactured in.
The study showed that the composite endpoints consisting of cardiac death, target vessel MI and clinically indicated repeat procedures at 12 months were similar for both.
Thus proving that India made stent Supraflex was as good as the market leader Finance, Dr. Kaul claimed.
The study has important economic implications in countries where the cost of the stent is an important issue. The full paper of this trial will soon be published in the Lancet, he said.
Dr. Kaul further called upon other Indian manufacturers to do similar clinical trials to prove that their devices are worthy competitors to those made abroad. These trials should be published in peer-reviewed journals.